Great post Respert. Adding here based on the linked in
Great post Respert. Adding here based on the linked in video of Dr Jay being honored with an award by his High School his age is roughly 65. Unless he has the genetics of Jeanne Calment who lived to 122, inhaling cigarette smoke and drinking French wine until very late, I think Dr Jay will stick with the higher priority which is to get Leronlimab launched on that trebuchet where it will go far and make in impact. That logic implies he won’t cede the rest of his life building big pharma. He has also explicitly stated he wants what is fair to shareholders. Whatever is going on now in the French wine stained and Cigar smoke filled Cytodyn board room will hopefully be revealed soon, preferably before those 200% tariffs take effect on French wine.
9
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
U.S. Latino leaders gathered for a historic delegation to Mexico, coinciding with the inauguration of Dra. Claudia Sheinbaum Pardo as Mexico's first female president back in 2024. This was no ordinary trip; it was a strategic move to tighten bonds between the two nations at a pivotal moment, hoping to reshape how Mexican-Americans influenced U.S. policy. Binational Ties:...
Continue Reading
The Future of Structural Heart Devices Market Growth The structural heart devices market is on an impressive growth trajectory, projected to reach approximately USD 25 billion within the coming years. This expansion is primarily driven by the escalating demand for innovative solutions to manage various structural heart conditions. Understanding Structural Heart Devices...
Continue Reading
Significant Changes at MediPharm Labs MediPharm Labs Corp. (TSX: LABS, OTCQX: MEDIF), a leader in pharmaceutical-quality cannabis extraction and hemp-based products, has announced the departure of its President and Co-Founder, Keith Strachan, from his management role. Effective immediately, Keith will transition to the Board of Directors, where his strategic input will...
Continue Reading
Interactive Brokers Group Reports Strong Financial Growth Interactive Brokers Group (NASDAQ: IBKR) has announced impressive financial results for the third quarter of 2024, capitalizing on a beneficent market following a U.S. interest rate cut. The company experienced significant year-over-year growth across key metrics such as client accounts, equity, and revenue....
Continue Reading
Overview of Recent Share Trading Activities Publicis Groupe has recently engaged in trading its own shares as part of a program approved during its Shareholders’ Meetings. This initiative underscores the company's commitment to managing its share capital effectively, reflecting its ongoing strategy to enhance shareholder value. Transaction Details During the designated...
Continue Reading
